Mauna Kea Technologies Announces Strongest Scientific Exposure Ever With More Than 40 Communications on Cellvizio(R) at Digestive Disease Week 2013
41 New Abstracts and Study Results Will Be Presented as Part of the Scientific Program; Highlights Include Exciting New Data on the Impact and Use of Optical Biopsies During Fine Needle Aspiration Procedures and the Diagnosis and Treatment of Many of the Most Pervasive Digestive Diseases Including Inflammatory Bowel Disease (IBD), Stomach Cancer and Esophageal Cancer; New AQ-Flex(TM) 19 Miniprobe -- the World's Smallest Microscope That Fits Through a Needle -- on Display at Booth 759
(firmenpresse) - PARIS -- (Marketwired) -- 05/17/13 -- Mauna Kea Technologies (EURONEXT PARIS: MKEA), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, today announced that 41 presentations at Digestive Disease Week (DDW) 2013 will highlight the use of optical biopsy across many of the most pervasive diseases in the gastrointestinal tract. Sixteen of the communications will be delivered through oral presentations and seven presentations will focus on needle-based optical biopsies, the newest application of Cellvizio technology that allows physicians to see cellular structures inside pancreatic cysts in the digestive tract in real time. DDW 2013 runs from May 18 to 21 in Orlando.
"The broad exposure of optical biopsy -- by far the strongest ever -- in the scientific program, is a reflection of the high-quality clinical work that is being performed around the world with Cellvizio," said David Carr-Locke, MD, Chief, Division of Digestive Diseases, Beth Israel Medical Center, New York. "We're very excited to see the application of the technology expand into new indications like inflammatory bowel disease and stomach cancer, as well as pancreatic cysts, where there is a significant unmet need for real-time diagnostic information beyond the information gained from endoscopic ultrasound-guided fine needle aspiration."
The newly FDA-cleared AQ-Flex 19 confocal miniprobe will be on display with the other Cellvizio miniprobes designed for use in the esophagus, biliary tract and colon at Mauna Kea Technologies' booth, #759.
"Importantly, there is also mounting evidence that only a short learning curve is required to interpret optical biopsy images and that a high number of trained physicians agree about the interpretation," Dr. Carr-Locke continued. Dr. Carr-Locke will be conducting a hands-on course on Cellvizio together with Dr. Mohammad Anwer at the local Florida Hospital Celebration Health in Orlando, on May 17. Demonstrations will also take place on May 19 and May 20 at the American Society for Gastrointestinal Endoscopy (ASGE) Learning Center.
"This will be the most successful and robust meeting of the year for optical biopsies with over 40 important new data presentations on the utility of our products," said Sacha Loiseau, CEO and Founder of Mauna Kea Technologies. "This data confirms that Cellvizio is making a clear impact in the diagnosis and treatment of disease in multiple areas, including the new frontier of pancreatic cysts."
The full schedule of Cellvizio optical biopsy presentations and events at DDW 2013 can be downloaded here:
DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 18 - 21, 2013, at the Orange County Convention Center, Orlando, FL. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at .
Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI tract, biliary and pancreatic ducts and lungs and during fine needle aspiration procedures.
For more information on Mauna Kea Technologies, visit
Erich Sandoval
Tel: +1 917 497 2867
NewInvestor Relations and Financial Communication
Pierre Laurent / Florent Alba
Tel: +33(0)1 44 71 94 94
Eric Cohen
Vice President, Finance
Tel: + 33 1 70 08 09 86
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 16.05.2013 - 23:30 Uhr
Sprache: Deutsch
News-ID 1228425
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
PARIS
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 257 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Mauna Kea Technologies Announces Strongest Scientific Exposure Ever With More Than 40 Communications on Cellvizio(R) at Digestive Disease Week 2013
"
steht unter der journalistisch-redaktionellen Verantwortung von
Mauna Kea Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
